公开(公告)号：US06552206B1

公开(公告)日：2003-04-22

申请号：US10138030

申请日：2002-05-02

Applicant: Bo Lin Zheng ,  Kan He ,  Yu Shao ,  Qun Yi Zheng

Inventor： Bo Lin Zheng ,  Kan He ,  Yu Shao ,  Qun Yi Zheng

IPC: C07C23100

CPC classification number: A61K36/31

Abstract: The invention relates to compositions that can be isolated from Lepidium plant material and to methods for their isolation. The compositions are useful for treating and preventing cancer and sexual dysfunction.

公开(公告)号：US06509371B1

公开(公告)日：2003-01-21

申请号：US09486117

申请日：2000-04-21

Applicant: Kan He ,  Paul F. Hollenberg ,  Thomas F. Woolf

Inventor： Kan He ,  Paul F. Hollenberg ,  Thomas F. Woolf

IPC: A61K3135

CPC classification number: A61K45/06 ,  A61K31/35 ,  A61K31/37 ,  A61K2300/00

Abstract: Bergamottin, principle compound in grapefruit juice responsible for inhibition of p450 3a4, the predominant p450 enzyme in the intestine, is coadministered with a compound having low bioavailability to a patient to increase oral bioavailability of the compound and pharmaceutical compositions of the same, as well as a method of isolating bg from grapefruit juice.

Abstract translation: 葡萄柚汁中的主要化合物是负责抑制p450 3a4（肠中主要的p450酶）的主要成分，与患者具有低生物利用度的化合物共同施用，以提高该化合物及其药物组合物的口服生物利用度，以及 从葡萄柚汁中分离出bg的方法。

公开(公告)号：US08951993B2

公开(公告)日：2015-02-10

申请号：US13402335

申请日：2012-02-22

Applicant: Baihua Hu ,  Kan He ,  Minsheng Zhang

Inventor： Baihua Hu ,  Kan He ,  Minsheng Zhang

IPC: A61K31/675 ,  A61K31/685 ,  C07F9/58 ,  C07F9/6509 ,  C07F9/6558

CPC classification number: C07F9/58 ,  C07F9/650952 ,  C07F9/65583

Abstract: The present invention relates to compounds represented by formula (I), which can modulate the activity of protein kinases. The invention also relates to a composition containing a compound of formula (I), and a method for synthesizing and using such compound for preventing or treating ALK or cMet mediated disorders or conditions.

Abstract translation: 本发明涉及可以调节蛋白激酶活性的由式​​（I）表示的化合物。 本发明还涉及包含式（I）化合物的组合物，以及用于合成和使用该化合物以预防或治疗ALK或cMet介导的病症或病症的方法。

公开(公告)号：US20140031358A1

公开(公告)日：2014-01-30

申请号：US14004633

申请日：2012-03-12

Applicant: Dong Liu ,  Minsheng Zhang ,  Kan He ,  Lianshan Zhang

Inventor： Dong Liu ,  Minsheng Zhang ,  Kan He ,  Lianshan Zhang

IPC: C07D239/96 ,  C07D403/10 ,  C07D487/04 ,  C07D403/12 ,  C07D405/12 ,  C07D471/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D413/12

CPC classification number: C07D239/96 ,  C07D239/80 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/10 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  C07D471/04 ,  C07D487/04

Abstract: The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts or prodrugs thereof, which inhibit the poly(ADP-ribose) polymerases (PARP) and therefore are useful for treating diseases, disorders, and conditions related to PARP. The present invention also discloses pharmaceutical compositions comprising a compound of formula (I), and methods of using such compounds to inhibit PARP enzymes, and to treat diseases, disorders, and conditions related to PARP.

Abstract translation: 本发明公开了抑制聚（ADP-核糖）聚合酶（PARP）的式（I）化合物或其药学上可接受的盐或前药，因此可用于治疗与PARP相关的疾病，病症和病症。 本发明还公开了包含式（I）化合物的药物组合物，以及使用这些化合物抑制PARP酶以及治疗与PARP有关的疾病，病症和病症的方法。

公开(公告)号：US20120058210A1

公开(公告)日：2012-03-08

申请号：US13294058

申请日：2011-11-10

Applicant: KAN HE ,  Marc ROLLER ,  Antoine BILY ,  Naisheng BAI ,  Jacques DIKANSKY ,  Alvin IBARRA

Inventor： KAN HE ,  Marc ROLLER ,  Antoine BILY ,  Naisheng BAI ,  Jacques DIKANSKY ,  Alvin IBARRA

IPC: A61K36/63 ,  A61P3/10

CPC classification number: A61K36/63 ,  A61K31/7088

Abstract: A Fraxinus excelsior seed extract that can be administered for therapeutic treatment of a subject, including a human, by blocking fat synthesis, activating PPAR-alpha, increasing hypoglycemic activity, reducing bodyweight, controlling fasting plasma insulin levels against hyperinsulinemia, and promoting insulin sensitivity and causing a beneficial acute insulinotropic effect. The Fraxinus excelsior seed extract includes, inter alia, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl)methyl ester, commonly called excelside A, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl) 2-(4-hydroxyphenyl)ethyl ester, commonly called excelside B, and the compounds GI5, GI3, nuzhenide, and oleoside dimethyl ester.

Abstract translation: 可以通过阻断脂肪合成，激活PPAR-α，增加降血糖活性，降低体重，控制空腹血浆胰岛素水平与高胰岛素血症的关系，以及促进胰岛素敏感性以及促进胰岛素敏感性的方法，将Fraxinus excelsior种子提取物用于治疗受试者（包括人） 引起有益的急性促胰岛素作用。 Fraxinus excelsior种子提取物尤其包括分离的化合物（2S，3E，4S）2H-吡喃-4-乙酸-3-亚乙基-2 - [（6-O- [b] -D-吡喃葡萄糖基 - D-吡喃葡萄糖基）氧基] -3,4-二氢-5-（甲氧基羰基）甲酯，通常称为excelside A，分离的化合物（2S，3E，4S）2H-吡喃-4-乙酸-3-亚乙基 - 2 - [（6-O-和bgr-D-吡喃葡萄糖基-β-吡喃葡萄糖基）氧基] -3,4-二氢-5-（甲氧基羰基）2-（4-羟基苯基）乙酯，通常称为excelside B ，和化合物GI5，GI3，硝酸ide酯和油甙二甲酯。

公开(公告)号：US20060057228A1

公开(公告)日：2006-03-16

申请号：US11178239

申请日：2005-07-08

Applicant: Qun Zheng ,  Bo Zheng ,  Kan He ,  Bao Cui ,  Naisheng Bai

Inventor： Qun Zheng ,  Bo Zheng ,  Kan He ,  Bao Cui ,  Naisheng Bai

IPC: A61K36/82 ,  A61K36/75 ,  A61K36/484 ,  A61K31/375 ,  A61K31/198

CPC classification number: A61K31/375 ,  A23L33/105 ,  A23L33/30 ,  A61K31/198 ,  A61K36/185 ,  A61K36/48 ,  A61K36/484 ,  A61K36/704 ,  A61K36/75 ,  A61K36/82 ,  A61K2300/00

Abstract: The present invention provides a dietary supplement and methods of using the same to promote body weight reduction and/or loss of body fat in a subject, and for the management of obesity. The supplement can further be used to reduce one or more metabolic parameters in a subject, such as blood glucose levels, blood triglyceride levels, and blood cholesterol levels.

Abstract translation: 本发明提供了一种饮食补充剂及其使用方法，以促进受试者体重减轻和/或体内脂肪的丧失，以及肥胖的管理。 该补充剂可进一步用于减少受试者中的一种或多种代谢参数，例如血糖水平，血液甘油三酯水平和血液胆固醇水平。

公开(公告)号：US20050171081A1

公开(公告)日：2005-08-04

申请号：US11089645

申请日：2005-03-25

Applicant: Baoliang Cui ,  Bo Lin Zheng ,  Kan He ,  Qun Yi Zheng

Inventor： Baoliang Cui ,  Bo Lin Zheng ,  Kan He ,  Qun Yi Zheng

IPC: C07D233/10 ,  C07D233/56 ,  A61K31/54

CPC classification number: C07D233/58

Abstract: The present invention relates to novel imidazole alkaloid compounds that have been isolated as a form of chloride salt from a root extract of Lepidium meyenii Walp, with the common name Maca, and identified below as 1,3-bis(phenylmethyl)-4,5-dimethyl-1H-imidazlium chloride and 1,3-bis(phenylmethyl)-2,4,5-trimethyl-1H-imidazlium chloride, compounds (1) and (2), respectively. The present invention further relates to the use of these novel compounds (1) and (2) to treat proliferative diseases, such as but not limited to cancer.

Abstract translation: 本发明涉及以通用名称Maca从马铃薯Lepidium meyenii Walp的根提取物中分离为氯化物形式的新型咪唑生物碱化合物，以下鉴定为1,3-双（苯基甲基）-4,5 - 二甲基-1H-咪唑氯化物和1,3-双（苯基甲基）-2,4,5-三甲基-1H-咪唑鎓氯化物，化合物（1）和（2）。 本发明还涉及这些新化合物（1）和（2）用于治疗增殖性疾病（例如但不限于癌症）的用途。

公开(公告)号：US06682697B2

公开(公告)日：2004-01-27

申请号：US10046927

申请日：2002-01-15

Applicant: Kan He ,  Baoliang Cui ,  Zhong Guan Shao ,  Natalie I. Koether ,  Val Madis ,  Qun Yi Zheng

Inventor： Kan He ,  Baoliang Cui ,  Zhong Guan Shao ,  Natalie I. Koether ,  Val Madis ,  Qun Yi Zheng

IPC: A61C200

CPC classification number: A61L2/186 ,  A61L2/0088 ,  A61L2/22 ,  A61L2202/122

Abstract: The present invention relates generally to the sterilization and disinfection of agricultural and botanical products such as botanical powders. More particularly, the present invention is directed towards the use of HBS technology whereby contaminated agricultural products are contacted, at ambient pressure, with an oxidant such as nascent oxygen or hydroxyl radicals thus resulting in the oxidization and destruction of the contaminating microorganisms.

Abstract translation: 本发明一般涉及农药和植物产品如植物粉末的灭菌和消毒。 更具体地，本发明涉及使用HBS技术，其中污染的农产品在环境压力下与氧化剂例如新生氧气或羟基自由基接触，从而导致污染微生物的氧化和破坏。

公开(公告)号：US20120220551A1

公开(公告)日：2012-08-30

申请号：US13402335

申请日：2012-02-22

Applicant: Baihua Hu ,  Kan He ,  Minsheng Zhang

Inventor： Baihua Hu ,  Kan He ,  Minsheng Zhang

IPC: A61K31/675 ,  A61P35/00 ,  C07F9/6509 ,  C07F9/58 ,  C07F9/6558

CPC classification number: C07F9/58 ,  C07F9/650952 ,  C07F9/65583

Abstract: The present invention relates to compounds represented by formula (I), which can modulate the activity of protein kinases. The invention also relates to a composition containing a compound of formula (I), and a method for synthesizing and using such compound for preventing or treating ALK or cMet mediated disorders or conditions.

Abstract translation: 本发明涉及可以调节蛋白激酶活性的由式​​（I）表示的化合物。 本发明还涉及包含式（I）化合物的组合物，以及用于合成和使用该化合物以预防或治疗ALK或cMet介导的病症或病症的方法。

公开(公告)号：US08142826B2

公开(公告)日：2012-03-27

申请号：US12185649

申请日：2008-08-04

Applicant: Kan He ,  Marc Roller ,  Antoine Bily ,  Naisheng Bai ,  Jacques Dikansky ,  Alvin Ibarra

Inventor： Kan He ,  Marc Roller ,  Antoine Bily ,  Naisheng Bai ,  Jacques Dikansky ,  Alvin Ibarra

IPC: A61K36/63

CPC classification number: A61K36/63 ,  A61K31/7088

Abstract: A Fraxinus excelsior seed extract that can be administered for therapeutic treatment of a subject, including a human, by blocking fat synthesis, activating PPAR-alpha, increasing hypoglycemic activity, reducing bodyweight, controlling fasting plasma insulin levels against hyperinsulinemia, and promoting insulin sensitivity and causing a beneficial acute insulinotropic effect. The Fraxinus excelsior seed extract includes, inter alia, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-β-D-glucopyranosyl-β-D-glucopyranosyl) oxy]-3,4-dihydro-5-(methoxycarbonyl)methyl ester, commonly called excelside A, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl) 2-(4-hydroxyphenyl)ethyl ester, commonly called excelside B, and the compounds GI5, GI3, nuzhenide, and oleoside dimethyl ester.

Abstract translation: 可以通过阻断脂肪合成，激活PPAR-α，增加降血糖活性，降低体重，控制空腹血浆胰岛素水平与高胰岛素血症的关系，以及促进胰岛素敏感性以及促进胰岛素敏感性的方法，将Fraxinus excelsior种子提取物用于治疗受试者（包括人） 引起有益的急性促胰岛素作用。 Fraxinus excelsior种子提取物尤其包括分离的化合物（2S，3E，4S）2H-吡喃-4-乙酸-3-亚乙基-2 - [（6-O- [b] -D-吡喃葡萄糖基 - D-吡喃葡萄糖基）氧基] -3,4-二氢-5-（甲氧基羰基）甲酯，通常称为excelside A，分离的化合物（2S，3E，4S）2H-吡喃-4-乙酸-3-亚乙基 - 2 - [（6-O-和bgr-D-吡喃葡萄糖基-β-吡喃葡萄糖基）氧基] -3,4-二氢-5-（甲氧基羰基）2-（4-羟基苯基）乙酯，通常称为excelside B ，和化合物GI5，GI3，硝酸ide酯和油甙二甲酯。